title: Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients.
abstract: BACKGROUND
  A novel gammaretrovirus named xenotropic murine leukemia virus-related virus (XMRV) has been recently identified and found to have a prevalence of 40% in prostate tumor samples from American patients carrying a homozygous R462Q mutation in the RNaseL gene. This mutation impairs the function of the innate antiviral type I interferon pathway and is a known susceptibility factor for prostate cancer. Here, we attempt to measure the prevalence of XMRV in prostate cancer cases in Germany and determine whether an analogous association with the R462Q polymorphism exists.
  
  
  RESULTS
  589 prostate tumor samples were genotyped by real-time PCR with regard to the RNaseL mutation. DNA and RNA samples from these patients were screened for the presence of XMRV-specific gag sequences using a highly sensitive nested PCR and RT-PCR approach. Furthermore, 146 sera samples from prostate tumor patients were tested for XMRV Gag and Env antibodies using a newly developed ELISA assay. In agreement with earlier data, 12.9% (76 samples) were shown to be of the QQ genotype. However, XMRV specific sequences were detected at neither the DNA nor the RNA level. Consistent with this result, none of the sera analyzed from prostate cancer patients contained XMRV-specific antibodies.
  
  
  CONCLUSIONS
  Our results indicate a much lower prevalence (or even complete absence) of XMRV in prostate tumor patients in Germany. One possible reason for this could be a geographically restricted incidence of XMRV infections.
authors.affiliation: Robert Koch-Institute, Centre for Biological Safety 4, Nordufer 20, 13353 Berlin, Germany. HohnO@rki.de
authors.forename: Oliver
authors.initials: O
authors.lastname: Hohn
authors.forename: Hans
authors.initials: H
authors.lastname: Krause
authors.forename: Pia
authors.initials: P
authors.lastname: Barbarotto
authors.forename: Lars
authors.initials: L
authors.lastname: Niederstadt
authors.forename: Nadine
authors.initials: N
authors.lastname: Beimforde
authors.forename: Joachim
authors.initials: J
authors.lastname: Denner
authors.forename: Kurt
authors.initials: K
authors.lastname: Miller
authors.forename: Reinhard
authors.initials: R
authors.lastname: Kurth
authors.forename: Norbert
authors.initials: N
authors.lastname: Bannert
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004279:DNA, Viral / Q000235:genetics / Q000302:isolation & purification; D004797:Enzyme-Linked Immunosorbent Assay; D015683:Gene Products, gag / Q000235:genetics / Q000276:immunology; D005858:Germany; D006801:Humans; D009052:Leukemia Virus, Murine / Q000235:genetics / Q000302:isolation & purification*; D008297:Male; D051379:Mice; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D015995:Prevalence; D011471:Prostatic Neoplasms / Q000453:epidemiology / Q000821:virology*; D012367:RNA, Viral / Q000235:genetics / Q000302:isolation & purification; D012192:Retroviridae Infections / Q000453:epidemiology* / Q000821:virology; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D014412:Tumor Virus Infections / Q000453:epidemiology* / Q000821:virology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral; D015683:Gene Products, gag; D012367:RNA, Viral; D014759:Viral Envelope Proteins